Intravenous octreotide test predicts the long term outcome of treatment with octreotide-long-acting repeatable in active acromegaly

Intravenous octreotide reduces GH to concentrations <5 mU/L in ∼50% of consecutive patients with active acromegaly, which predicts a good response to chronic octreotide-LAR treatment.